(6S,7S)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2,5)octane-7-carboxylic acid | 791834-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (6S,7S)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2,5)octane-7-carboxylic acid
• 英文别名: (6S,7S)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-7-carboxylic acid
• CAS: 791834-68-9
• 化学式: C₁₉H₂₅N₃O₃
• 分子量: 343.426
• InChiKey: IJUUXSGKJITKQH-HOTGVXAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  72.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (6S,7S)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2,5)octane-7-carboxylic acid 在 5% palladium on barium sulphate 、 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 28.58h， 生成 tetrahydro-2H-pyran-4-yl (6S,7S)-7-((hydroxyamino)carbonyl)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2,5)octane-5-carboxylate
  参考文献：
  名称：

  AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES

  摘要：

  公开号：

  EP1622569B1
• 作为产物：
  描述：

  tert-butyl (6S,7S)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2,5)octane-7-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (6S,7S)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2,5)octane-7-carboxylic acid
  参考文献：
  名称：

  Discovery of a Potent, Selective, and Orally Active Human Epidermal Growth Factor Receptor-2 Sheddase Inhibitor for the Treatment of Cancer

  摘要：

  The design, synthesis, evaluation, and identification of a novel class of (6S,7S)-N-hydroxy-6-carboxamide-5-azaspiro[2.5]octane-7-carboxamides as the first potent and selective inhibitors of human epidermal growth factor receptor-2 (HER-2) sheddase is described. Several compounds were identified that possess excellent pharmacodynamic and pharmacokinetic properties and were shown to decrease tumor size, cleaved HER-2 extracellular domain plasma levels, and potentiate the effects of the humanized anti-HER-2 monoclonal antibody (trastuzumab) in vivo in a HER-2 overexpressing cancer murine xenograft model.

  DOI：

  10.1021/jm061344o

文献信息

• Aza spiro alkane derivatives as inhibitors of metalloproteases
  申请人：——

  公开号：US20040259896A1

  公开（公告）日：2004-12-23

  The present invention provides a compound of Formula I or Formula II: 1 enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

  本发明提供了公式I或公式II的化合物：1对映异构体，对映体，前药，溶剂化物，代谢物或其药学上可接受的盐，其中组分变量在此处提供。公式I和II的化合物是金属蛋白酶调节剂，可用于治疗与金属蛋白酶活性相关的疾病，如关节炎，癌症，心血管疾病，皮肤疾病，炎症和过敏症。
• AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES
  申请人：Yao Wenqing

  公开号：US20090124649A1

  公开（公告）日：2009-05-14

  The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

  本发明提供了I式或II式的化合物：其对映异构体、顺反异构体、前药、溶剂化物、代谢物或其药学上可接受的盐，其中所述的组分变量已在此处提供。I和II式的化合物是金属蛋白酶的调节剂，并且在治疗与金属蛋白酶活性相关的疾病，例如关节炎、癌症、心血管疾病、皮肤疾病、炎症和过敏症方面很有用。
• AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES
  申请人：Yao Wenqing

  公开号：US20110288068A1

  公开（公告）日：2011-11-24

  The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

  本发明提供了化合物I或化合物II的化合物：对映体、顺反异构体、前药、溶剂化物、代谢物或其药学上可接受的盐，其中组成变量在此处提供。化合物I和II是金属蛋白酶调节剂，可用于治疗与金属蛋白酶活性相关的疾病，如关节炎、癌症、心血管疾病、皮肤疾病、炎症和过敏症。
• Aza spiro alkane derivatives as inhibitors of metallproteases
  申请人：Incyte Corporation

  公开号：EP2617419A1

  公开（公告）日：2013-07-24

  The present invention provides a compound of Formula (I) or Formula (II): enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula (I) and (II) are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

  本发明提供了式(I)或式(II)化合物：其对映体、非对映体、原药、溶物、代谢物或药学上可接受的盐，其中组成变量在此提供。 式（I）和（II）化合物是金属蛋白酶的调节剂，可用于治疗与金属蛋白酶活性相关的疾病，如关节炎、癌症、心血管疾病、皮肤疾病、炎症和过敏性疾病。
• Design and identification of selective HER-2 sheddase inhibitors via P1′ manipulation and unconventional P2′ perturbations to induce a molecular metamorphosis
  作者：Wenqing Yao、Jincong Zhuo、David M. Burns、Yun-Long Li、Ding-Quan Qian、Colin Zhang、Chunhong He、Meizhong Xu、Eric Shi、Yanlong Li、Cindy A. Marando、Maryanne B. Covington、Gengjie Yang、Xiangdong Liu、Max Pan、Jordan S. Fridman、Peggy Scherle、Zelda R. Wasserman、Gregory Hollis、Kris Vaddi、Swamy Yeleswaram、Robert Newton、Steve Friedman、Brian Metcalf

  DOI：10.1016/j.bmcl.2007.10.108

  日期：2008.1

  In an effort to obtain a MMP selective and potent inhibitor of HER-2 sheddase (ADAM-10), the P1' group of a novel class of (6S,7S)-7-[(hydroxyamino)carbonyl]-6-carboxamide-5-azaspiro[2.5]octane-5-carboxylates was attenuated and the structure-activity relationships (SAR) will be discussed. In addition, it was discovered that unconventional perturbation of the P2' moiety could confer MMP selectivity, which was hypothesized to be a manifestation of the P2' group effecting global conformational changes. (C) 2007 Elsevier Ltd. All rights reserved.